A venture capital platform associated with a leading global life sciences services provider manages multiple funds and focuses on investing in early-stage life science companies. The firm’s investment sweet spot spans from Seed through Series B stages. Initial check sizes typically range from USD $2–10M, with the ability to provide follow-on capital. The firm is open to both leading and co-investing and considers board or observer seats on a case-by-case basis. Backed by a major contract research organization, the firm leverages deep expertise in biotech research and development to deliver value beyond capital.
The firm invests in biotech therapeutics, including small molecules, biologics, and drug discovery programs. Key areas of interest include oncology, immunology and inflammation, central nervous system diseases, and metabolic diseases, covering a broad range of commonly pursued indications. The firm evaluates opportunities from the pre-IND stage through Phase I clinical trials. In addition, the firm focuses on innovative AI-enabled healthcare opportunities with strong technological differentiation, including AI-integrated medical devices such as surgical robotics, brain–computer interfaces, and smart imaging systems, as well as AI-driven diagnostics, drug discovery acceleration platforms, and intelligent healthcare solutions designed to improve clinical efficiency and data-driven decision-making.
The firm does not impose specific requirements regarding the composition of a company’s management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment